Blog

Going into 2027, a cash-pay patient can buy Wegovy or Ozempic for $349 a month from NovoCare, the Wegovy pill from $149, Zepbound from $299 to $449 on LillyDirect and Foundayo from $149. Novo's list-price cut to $675 on January 1 helps insured patients with deductibles; it does not move those cash prices. So a telehealth brand's price is its program fee, and this post works out what that fee earns at $49, $99 and $149, and which structures we would use.

The Business Group on Health's August survey found 14% of employers have dropped or plan to drop GLP-1 weight-loss coverage by 2027, and coverage among surveyed employers fell from 72% in 2025 to 60% in 2026. Those employees are reading their benefits guides right now and lose coverage on January 1. Most will try to stay on the drug at cash prices. This is the operator view: which patients are in the wave, what each wants in the first week of January, and the four things a brand needs in place to keep their dose going.

Is it too late to start a GLP-1 telehealth business? Too late for the 2024 version, where a $99 compounded vial and a Facebook ad account made a company. Not too late for the version that is actually working in the third quarter of 2026: a niche, a retention system, branded drugs the manufacturer ships, and fixed costs low enough that 500 patients is a business. Here is what died, what the numbers say still works, and the three things that now count as a moat.

Novo filed CagriSema on December 18, 2025 and says a US decision is expected in Q4 2026, with no public PDUFA date. Retatrutide has drifted to an early-2027 filing, which makes CagriSema the next-molecule drill your program actually has to run. Readiness is not predicting the outcome: it is education pages on an update rhythm, formulary logic that adds a molecule as configuration, pricing scenarios drafted in advance, and a day-one kit ready to ship within hours.

Every October, plan documents land and a wave of patients discovers their GLP-1 coverage changes January 1. They are not new leads: they are experienced patients, mid-treatment, angry at a decision someone else made about their care. The funnel that receives them well, dedicated landing page, coverage-aware intake, honest bridge pricing, gets designed in September. Here is the blueprint, including the copy that works and the copy that repels.

The comment period closed July 30. The FDA's final order on compounded semaglutide, tirzepatide, and liraglutide now has no remaining procedural step with a date attached: it can publish any week, and it will land on someone's ordinary Tuesday. This is the 72-hour run-book to write now and execute later: the patient email with blanks, the pricing-page swap, the pharmacy confirmations, the support macros, the day-one post, and the claims that get warning letters.

In the span of two months, weight maintenance went from an under-studied afterthought to a field with fresh evidence: a major journal review on post-discontinuation regain, new maintenance-focused trial designs, and behavioral studies launching at academic centers. For operators, the shift matters commercially: maintenance programs can now be built on cited evidence rather than intuition, and evidence-built programs win the patients, the partners, and the AI answers. Here is what the new data says and how to encode it.

The trial results are public: the leading triple agonist delivered average weight loss approaching thirty percent, bariatric-surgery territory from a weekly injection, with a filing expected before year-end. Whenever it arrives, it resets what patients expect, what protocols must monitor, and what programs must be able to support. The operators who upgrade their care architecture now will be ready on approval day. Here is what the 30% era demands.

Medicare's GLP-1 Bridge went live on July 1, and the first weeks have been a masterclass in the difference between a covered benefit and a working workflow. The central-processor prior authorization, the 5-to-14-day turnaround, the eligibility questions patients cannot answer themselves: each is an operations problem, and the programs that solved them on paper in June are enrolling seniors in July. Here is what the early weeks teach.

For the first time, a weight program can be designed pill-first. Two oral GLP-1s are on the market, patients are asking for them by name, and the operational profile of a tablet program is different from an injectable one in almost every way that matters: intake, titration, refills, fulfillment, and the daily relationship with the patient. Here is how to design a program around the pill, rather than bolting the pill onto an injection workflow.

The second half of 2026 is stacked with decisions that will reshape metabolic telehealth: the 503B final order, the July peptide committee, a possible CagriSema approval, a retatrutide filing (now expected in Q1 2027), and open enrollment. Operators who build ahead of each date will catch the demand wave. Operators who wait will read about it. Here is the calendar, and what to have ready before each entry.

Millions of patients are reaching their GLP-1 goals, and the question they ask next, how do I keep this, is becoming its own care category. Weight maintenance is the most underbuilt vertical in telehealth: a motivated population, a real clinical playbook spanning taper protocols, low-dose continuation, strength preservation, and metabolic monitoring, and almost nobody offering it as a designed program. This is the product spec.

The Medicare GLP-1 Bridge went live on July 1, opening branded GLP-1 access to millions of older adults through a low fixed monthly copay. It is the largest single expansion of the addressable GLP-1 population telehealth has seen, and most DTC programs were designed for a 35-year-old on a phone, not a 68-year-old managing multiple conditions. This is the operator playbook for serving the 65+ patient well: intake design, eligibility screening, caregiver flows, clinical coordination, and the retention patterns that fit this population.

Mid-2026 marks the start of the branded GLP-1 era. Reliable manufacturer supply, transparent pricing, and direct-to-patient channels have turned access into a solved problem. That is great news for operators who want to build durable, care-first programs. This is the playbook for building a GLP-1 telehealth business that wins on experience, adherence, and longitudinal care in the branded era.

A microdosing GLP-1 patient is not a smaller version of a standard GLP-1 patient. They arrive with different motivations, different expectations, and a different definition of success. The intake, onboarding, milestones, side-effect support, and outcome story should reflect that. This is the operator playbook for the first 90 days of a microdosing program done well.

The 30-day soft launch is the starting line, not the finish line. The next 60 to 90 days are where a real program emerges: scaling the funnel that worked, building provider capacity before the backlog forms, retiring the manual workarounds, and shipping the items you deliberately deferred. This is the founder playbook for the second sprint.

A focused founder can take a GLP-1 telehealth business from incorporation to first patient served in 30 days. The category is mature enough, the infrastructure is fast enough, and the path is clear enough that 30 days is the right ambition. This is the week-by-week plan that gets you there with a real program, not a half-built one.

An online weight loss clinic in late 2026 sells branded GLP-1s at manufacturer cash prices ($149 to $449 a month), a clinical relationship, and retention, in a market where CVS charges $29 a visit and the compounded-copy era ended with the Fifth Circuit's August 27 ruling. This is the founder's playbook: what the clinic sells now, who can own one, why the platform decision is where the cost lives, and where the opportunity is still open.

Semaglutide now has an FDA-approved indication for MASH with moderate to advanced fibrosis. That opens a genuinely new DTC telehealth program category, and it is not a weight loss intake with a liver enzyme question bolted on. A MASH program needs its own clinical architecture, its own labs and imaging coordination, and its own retention and compliance posture.

The strongest 2026 evidence is moving GLP-1 care past pure weight loss. SELECT showed cardiovascular protection. STEP-HFpEF showed symptom improvement in heart failure with preserved ejection fraction. FLOW showed kidney protection in CKD. ESSENCE showed MASH resolution and led to FDA approval for liver disease. A new low-dose preprint shows cardiac and hepatic benefit independent of weight loss. That changes intake, provider review, and the entire DTC positioning question.